Delivery Order SPE2DB20D3103-SPE2DB26FL4E1
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $8,123.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 75 mg capsules (21-count package) on August 1, 2025, with an ultimate completion date of August 22, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ibrance 125 mg capsules (21-count packaging). This is a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. The order is scheduled for completion by October 9, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ibrance 125 mg capsules (21-count units). This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The contract performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of September 16, 2025. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Ibrance 125 mg capsules (21-count packages) under a firm fixed-price contract valued at $8,118.08, with completion scheduled for August 22, 2025. This non-set-aside, competitively awarded delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical vendor within the DLA's medical supply chain. The product will be delivered to...
- The Defense Logistics Agency awarded a $8,118.08 delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Ibrance 125 mg capsules (21-count packages). This firm fixed-price, competitively awarded contract is scheduled for completion by October 20, 2025, and represents performance at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award carries no set-aside designation and is issued as a child order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (quantity 21) under a firm fixed-price contract valued at $8,555.21. The delivery order, issued on October 23, 2025, carries an ultimate completion date of November 14, 2025. This non-set-aside award represents a single transaction within AmerisourceBergen's broader federal pharmaceutical supply portfolio and will be performed at the company's corporate office location...
- The Defense Logistics Agency awarded a $24,354.24 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 21 capsules of Ibrance 125 mg on September 26, 2025, with an ultimate completion date of October 20, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was used in this competitive award, reflecting the contractor's established capability to meet federal pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (21-count) on August 19, 2025, with completion targeted for September 10, 2025. The contract utilizes firm fixed pricing and was competitively awarded without a set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ibrance 125 mg tablets in a quantity of seven units, with a ceiling value of $8,118.08. This firm fixed-price delivery order, which is expected to be completed by September 10, 2025, carries no set-aside designation and represents a competitively awarded transaction. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $24,367.44 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg capsules (21-count package) on August 27, 2025, with an ultimate completion date of September 18, 2025. This competitive award uses firm fixed pricing and carries no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in that...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB26FL4E1Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,118.09 to AmerisourceBergen Drug Corp for 21 capsules of Ibrance 125 mg on October 28, 2025, with completion expected by November 19, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The pharmaceutical product will be supplied from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to military healthcare systems worldwide. Ibrance, a oncology medication, represents one of the specialized pharmaceutical products within AmerisourceBergen's extensive portfolio of brand-name and generic drugs supporting federal medical procurement needs for the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.1k | 10/28/25 |